About Verona Pharma
Verona Pharma is a company based in London (United Kingdom) founded in 2005 was acquired by Merck in July 2025. Verona Pharma has raised $56.02 million across 4 funding rounds from investors including Merck, Orbimed and Janus Henderson Investors. The company has 209 employees as of December 31, 2024. Verona Pharma offers products and services including Respiratory Therapeutics and Pipeline Programs. Verona Pharma operates in a competitive market with competitors including aTyr Pharma, ReCode Therapeutics, GEn1E, Enterprise Therapeutics and Ikaria, among others.
- Headquarter London, United Kingdom
- Employees 209 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Verona Pharma Plc Sponsored Adr
-
Annual Revenue
$42.3 M (USD)0as on Dec 31, 2024
-
Net Profit
-$173.49 M (USD)-217.87as on Dec 31, 2024
-
EBITDA
-$153.63 M (USD)-128.79as on Dec 31, 2024
-
Total Equity Funding
$56.02 M (USD)
in 4 rounds
-
Latest Funding Round
$200.16 M (USD), Post-IPO
Jul 17, 2020
-
Investors
Merck
& 16 more
-
Employee Count
209
as on Dec 31, 2024
-
Acquired by
Merck
(Jul 09, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Verona Pharma
Verona Pharma is a publicly listed company on the NASDAQ with ticker symbol VRNA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Verona Pharma
Verona Pharma offers a comprehensive portfolio of products and services, including Respiratory Therapeutics and Pipeline Programs.
Develops treatments for chronic respiratory diseases like COPD.
Builds portfolio of novel respiratory drugs for various conditions.
People of Verona Pharma
Unlock access to complete
Unlock access to complete
Funding Insights of Verona Pharma
Verona Pharma has successfully raised a total of $56.02M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $200.16 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Verona Pharma
Verona Pharma has secured backing from 17 investors, including venture fund and institutional investors. Prominent investors backing the company include Merck, Orbimed and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
PE firm investing in the US
|
Locked | Locked | Locked | |
|
Venture capital funding is provided by Samsara BioCapital in California.
|
Locked | Locked | Locked |
Investor details for Verona Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Verona Pharma
Investment portfolio details for Verona Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Verona Pharma
Detailed financials for Verona Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Verona Pharma Comparisons
Peer comparison for Verona Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Verona Pharma
Verona Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as aTyr Pharma, ReCode Therapeutics, GEn1E, Enterprise Therapeutics and Ikaria, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Protein biologics are developed for treating rare diseases.
|
|
| Locked | Locked | Locked |
Precision medicines for lung-related diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of inflammatory and rare diseases
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of respiratory diseases such as cystic fibrosis
|
|
| Locked | Locked | Locked |
Therapies for respiratory-related cardiopulmonary disorders are developed.
|
Detailed competitors of Verona Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Verona Pharma
Complete news archive for Verona Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Verona Pharma
Verona Pharma was founded in 2005 and raised its 1st funding round 7 years after it was founded.
Verona Pharma is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Verona Pharma is a funded company, having raised a total of $56.02M across 4 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Verona Pharma is 209.
Annual revenue of Verona Pharma is $42.3M as on Dec 31, 2024.
Verona Pharma was founded in 2005 in London, United Kingdom, and operates in the pharmaceutical sector focused on respiratory conditions. A drug pipeline is maintained, including RPL-554 in Phase 2 trials for chronic obstructive pulmonary disease, cystic fibrosis, and asthma. VRP700 for cough management is available for out-licensing. Novel anti-inflammatory polysaccharides from marine organisms like starfish are also identified as sources without anticoagulant effects.
Verona Pharma's top competitors include aTyr Pharma, ReCode Therapeutics and Pulmatrix.
Verona Pharma offers Respiratory Therapeutics and Pipeline Programs.
Yes, Verona Pharma is publicly traded on NASDAQ under the ticker symbol VRNA.
Verona Pharma has 17 investors. Key investors include Merck, Orbimed, Janus Henderson Investors, RA Capital, and Perceptive Advisors.
The ticker symbol of Verona Pharma is VRNA on NASDAQ.